📊 BLGO Key Takeaways
Is Biolargo, Inc.. (BLGO) a Good Investment?
BioLargo demonstrates severe operational distress with negative operating margins of -191.3% and negative free cash flow of -8.3M despite achieving 2,383.8% revenue growth. The company is consuming cash at an unsustainable rate with only 3.9M in cash reserves against 6.8M in liabilities, indicating critical liquidity risk. Deteriorating fundamentals combined with substantial operating losses and negative returns on equity and assets suggest the company is not viable in its current operational structure.
BioLargo is showing exceptional top-line growth, but the quality of that growth is weak because it is still paired with deeply negative operating margins and heavy cash burn. Liquidity is thin and interest coverage is negative, so unless the company can convert recent revenue growth into sustainable gross profit and sharply reduce operating losses, its financial position remains fragile.
Why Buy Biolargo, Inc.. Stock? BLGO Key Strengths
- Exceptional revenue growth of 2,383.8% year-over-year demonstrates strong commercial traction
- Gross margin of 43.9% indicates viable unit economics and pricing power at the product level
- Moderate leverage with Debt/Equity ratio of 0.51x provides some balance sheet flexibility
- Revenue growth is extremely strong, indicating improving commercial traction
- Gross margin of 43.9% suggests the core products/services can generate meaningful gross profit
- Cash balance of $3.88M provides some near-term operating flexibility
BLGO Stock Risks: Biolargo, Inc.. Investment Risks
- Severe cash burn with operating cash flow of -8.3M and only 3.9M in cash reserves suggests runway of less than 6 months
- Operating losses of -14.9M far exceed gross profit of 3.4M indicating unsustainable cost structure and lack of operational leverage
- Negative interest coverage ratio of -27.5x demonstrates inability to service debt from operating income; company dependent on cash reserves
- Negative ROE of -291.4% and ROA of -141.7% indicate value destruction and inefficient asset deployment
- Current ratio of 1.01x demonstrates critically tight liquidity with minimal buffer for operational disruptions
- Operating margin of -191.3% shows the business is far from scale-efficient
- Free cash flow of -$8.32M and negative operating cash flow indicate ongoing dependence on external financing
- Current ratio of 1.01x and negative interest coverage point to tight liquidity and debt-servicing risk
Key Metrics to Watch
- Operating cash flow trend - critical indicator of sustainable operations and path to profitability
- Monthly cash burn rate and cash runway - survival metric given current burn rates
- Gross profit dollars and operating expense ratio - whether revenue growth will eventually drive operational leverage
- Debt covenant compliance and refinancing needs - refinancing risk given negative EBITDA
- Path to operating profitability - specific milestones and timeline for reaching positive operating income
- Operating cash flow improvement relative to revenue growth
- Operating margin trend and path toward breakeven
Biolargo, Inc.. (BLGO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Biolargo, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BLGO Profit Margin, ROE & Profitability Analysis
BLGO vs Materials Sector: How Biolargo, Inc.. Compares
How Biolargo, Inc.. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biolargo, Inc.. Stock Overvalued? BLGO Valuation Analysis 2026
Based on fundamental analysis, Biolargo, Inc.. shows some fundamental concerns relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biolargo, Inc.. Balance Sheet: BLGO Debt, Cash & Liquidity
BLGO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biolargo, Inc..'s revenue has grown significantly by 602% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
BLGO Revenue Growth, EPS Growth & YoY Performance
BLGO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.1M | -$1.1M | $0.00 |
| Q2 2025 | $2.8M | -$780.0K | $0.00 |
| Q1 2025 | $3.3M | -$775.0K | $0.00 |
| Q3 2024 | $2.7M | -$494.0K | $0.00 |
| Q2 2024 | $1.4M | -$494.0K | $0.00 |
| Q1 2024 | $3.7M | -$494.0K | $0.00 |
| Q3 2023 | $1.5M | -$494.0K | $0.00 |
| Q2 2023 | $1.3M | -$494.0K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biolargo, Inc.. Dividends, Buybacks & Capital Allocation
BLGO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biolargo, Inc.. (CIK: 0000880242)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BLGO
What is the AI rating for BLGO?
Biolargo, Inc.. (BLGO) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BLGO's key strengths?
Claude: Exceptional revenue growth of 2,383.8% year-over-year demonstrates strong commercial traction. Gross margin of 43.9% indicates viable unit economics and pricing power at the product level. ChatGPT: Revenue growth is extremely strong, indicating improving commercial traction. Gross margin of 43.9% suggests the core products/services can generate meaningful gross profit.
What are the risks of investing in BLGO?
Claude: Severe cash burn with operating cash flow of -8.3M and only 3.9M in cash reserves suggests runway of less than 6 months. Operating losses of -14.9M far exceed gross profit of 3.4M indicating unsustainable cost structure and lack of operational leverage. ChatGPT: Operating margin of -191.3% shows the business is far from scale-efficient. Free cash flow of -$8.32M and negative operating cash flow indicate ongoing dependence on external financing.
What is BLGO's revenue and growth?
Biolargo, Inc.. reported revenue of $7.8M.
Does BLGO pay dividends?
Biolargo, Inc.. does not currently pay dividends.
Where can I find BLGO SEC filings?
Official SEC filings for Biolargo, Inc.. (CIK: 0000880242) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BLGO's EPS?
Biolargo, Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BLGO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biolargo, Inc.. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BLGO stock overvalued or undervalued?
Valuation metrics for BLGO: ROE of -291.4% (sector avg: 14%), net margin of -151.7% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy BLGO stock in 2026?
Our dual AI analysis gives Biolargo, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BLGO's free cash flow?
Biolargo, Inc..'s operating cash flow is $-8.3M, with capital expenditures of $18.8K. FCF margin is -107.1%.
How does BLGO compare to other Materials stocks?
Vs Materials sector averages: Net margin -151.7% (avg: 10%), ROE -291.4% (avg: 14%), current ratio 1.01 (avg: 1.6).